According to the result, high expression of ANRIL is associated with a poor prognosis of digestive system tumors (HR = 1.69, 95% CI: 1.46–1.95, P < .0001) and other tumors (HR = 2.03, 95% CI: 1.61–2.57, P < .0001). Here, CDKN2B-AS1 is linked to digestive system neoplasm.